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a  b  s  t  r  a  c  t
The  safety  of  krill  powder  was  assessed  in  a  subchronic  13-week  toxicity  study  where  rats
were  fed  krill  powder  or control  diets.  The  krill  powder  inclusion  in the  test  diet was  9.67%
(w/w).  There  were  no  differences  noted  in  body  weight  or food  consumption  in either  gen-
der. Differences  in  clinical  chemistry  values  were  noted  in  the  krill powder-treated  animals,
but these  ﬁndings  were  of  no toxicological  signiﬁcance.  A signiﬁcant  decrease  in absolute
heart  weight,  but  not  relative  heart  weight,  was  observed  in  both  sexes  given  krill powder,Keywords:
Astaxanthin
Krill
Toxicity
Omega-3 fatty acids
Protein
although  no corresponding  histological  changes  were  observed.  Hepatocyte  vacuolation
was  noted  histologically  in males  fed  krill  powder.  This  ﬁnding  was  not  associated  with
other indications  of  hepatic  dysfunction.  The  no observed  adverse  effect  level  (NOAEL)  for
the conditions  of this  study  was  considered  to be 9.67%  krill  powder.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
The two omega-3 fatty acids eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) have been proven
to have a wide range of beneﬁcial effects, in particular on
cardiovascular health [1–5]. Fish and seafood intake is con-
sidered too low in a large proportion of the population in
the Western world, and to take omega-3 food supplements
is a way to improve one’s daily need of these important
fatty acids. To date, ﬁsh oils have been the most traditional
omega-3 supplements, but new sources of omega-3 fatty
acids, like algae and krill, are gaining popularity [6–8].
Krill are shrimp-like crustaceans that are harvested
commercially in the Antarctic Sea [9]. The estimated
Abbreviations: ANOVA, analysis of variance; ANCOVA, analysis of
covariance; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; KP,
krill  powder; NOAEL, no observed adverse effect level; SO, soya bean oil.
∗ Corresponding author. Tel.: +47 24 13 00 00; fax: +47 24 13 01 10.
E-mail address: kjetil.berge@akerbiomarine.com (K. Berge).
http://dx.doi.org/10.1016/j.toxrep.2014.11.011
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
amount of krill (Euphausia superba) in Antarctica is between
125 and 750 million metric tonnes (http://www.fao.org/
ﬁshery/species/3393/en), being one of the most abundant
animals on the planet. There are currently two  main prod-
ucts produced from krill: krill oil and krill powder. Krill
oil is sold as a food supplement and is characterised by a
large proportion of phospholipids, especially phosphatidyl-
choline (PC) [10]. The majority of EPA and DHA in krill oil
is esteriﬁed into PCs and omega-3 fatty acids in phospho-
lipid form have been shown to be efﬁciently taken up by
body tissues [11–14]. Also krill powder consists of a large
fraction of phospholipids (20.2%) and it further contains
proteins (41.7%) in addition to a lipid fraction (51.7%).
Besides the high presence of phospholipids, krill also
contains the red pigment molecule astaxanthin [15]. Astax-
anthin is an antioxidant carotenoid that gives krill powder
its reddish colour.The product has been used for both human and ani-
mal  dietary supplementation [16–18]. So far, krill powder
has been tested in two  pre-clinical [17,18] and one clin-
ical study [16]. The pre-clinical studies investigated the
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1
Composition of krill powder.
Compound % in krill powder
Total lipids 51.7
Phospholipids 24.7
Phosphatidylcholine 22.7
Phosphatidylethanolamine 1.7
Cholesterol esters 0.5
Triacylglycerol 25.3
Diacylglycerol 0.8
Proteins 41.7
Ash 5.4
Salt (NaCl) 2.1
Astaxanthin (mg/kg) 115.5
Fatty acids
14:0 6.0
16:0 8.9
18:0 0.6
20:0 0.1
22:0 n.d.
16:1 n-7 3.1
18:1 n-9 + n-7 + n-5 7.9
20:1 n-9 + n-7 0.5
22:1 n-11 + n-9 + n-7 0.2
24:1 n-9 0.1
16:2 n-4 0.3
16:3 n-4 0.2
18:2 n-6 1.0
18:3 n-6 0.2
20:2 n-6 0.1
20:3 n-6 0.1
20:4 n-6 0.2
22:4 n-6 n.d.
18:3 n-3 0.5
18:4 n-3 1.3
20:3 n-3 n.d.
20:4 n-3 0.2
20:5 n-3 6.2
21:5 n-3 0.2
22:5 n-3 0.2
22:6 n-3 2.7
SFA 15.7
MUFA 11.6
Omega-6 PUFA 1.4
Omega-3 PUFA 11.2
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA:K. Berge et al. / Toxicol
ffect of krill powder on hepatic gene regulation in healthy
ice [17] and on inﬂammation and lipid metabolism in
ice overexpressing TNF [18]. The clinical study exam-
ned krill powder supplementation in mildly obese men
nd its effect on fat distribution, blood lipid levels and the
ndocannabinoid system [16].
The objective of the present study was to assess the
afety of krill powder in a 13-week subchronic toxicity
tudy in Wistar rats.
. Materials and methods
.1. Test materials
SuperbaTM krill powder was provided by Aker BioMa-
ine Antarctic AS (Oslo, Norway). The raw material was
nalysed for fatty acid composition, total lipid, lipid classes,
roteins, ash, salt and astaxanthin content (Noﬁma AS,
ergen, Norway). The composition of the krill powder is
hown in Table 1. The amino acids proﬁle of krill powder
as been analysed previously [17].
.2. Subchronic toxicity study
The subchronic toxicity study was designed and con-
ucted based on the regulatory guidelines OPPTS 870.3100,
ECD No. 408 and US FDA Redbook. Twenty male and
wenty female Han Wistar rats were obtained from Charles
iver UK Limited. They were acclimatised for a period
f 14 days. The study was performed at Charles River,
ranent, Edinburgh, UK. The animals were approximately
even weeks old at treatment start and were in the weight
ange of 179–229 g (males) and 109–162 g (females). Ani-
als were randomised to cages on racks separated by
reatment group and sex and housed in the same room.
ontrol and krill powder groups were housed on sepa-
ate racks with two to three animals per cage. Rats were
iven food and water (domestic mains water) ad libitum
uring this period, and were provided with wooden chew
ticks for environmental enrichment (Tapvei Estonia OÜ,
arjumma, Estonia). The animals were kept at 19–23 ◦C,
0–70% humidity and a ﬁxed light cycle (light hours were
rom 7 to 19 h) throughout the study period. The study was
onducted in accordance with the OECD Principles of Good
aboratory Practice (GLP) as incorporated into the United
ingdom Statutory Instrument for GLP, and as accepted by
egulatory authorities throughout the European Commu-
ity, United States (FDA and EPA) and Japan (MHLW, MAFF
nd METI).
.3. Treatment
Two groups of ten male and ten female Han Wistar rats
ere fed diets containing a total of 8% oil for a period of
3 weeks. The control diet was supplemented with 8% soya
ean oil. The krill powder diet was incorporated with 9.67%
rill powder (corresponding to 5% krill oil). The krill pow-
er contained 20.2% PL, 51.7% total lipids, 41.7% proteins
nd 115.5 mg/kg astaxanthin (for more details see Table 1),polyunsaturated fatty acids; n.d.: not detected. Lower detection limit for
fatty acid measurements was 0.1 g/100 g. All amounts shown are gram per
100 g of krill powder, except for astaxanthin which is in mg/kg.
and the amounts of soy bean oil (3%) and casein added
to the krill powder diet were reduced in such a way  that
the lipid content and protein content were the same in
the two  test diets. This amount of krill powder is equal to
inclusion of 5% krill oil, which corresponds to 2.5–5 g/kg of
body weight. After conversion to human equivalent doses
(HED), the studied dose range provides a 24- to 48-fold
safety margin with the recommended supplement level
of 1 g/day.
The diets were based on the standard RM1  diet
(http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf) and pre-
pared by Special Diet Services (Witham, UK) according to
their in-house standard operating procedures.The krill powder diet was veriﬁed for homogeneity
by Noﬁma AS (Bergen, Norway). After inclusion of krill
powder into the ﬁnal diet form, the recovery of EPA and
DHA was 97.0 ± 0.7% and 96.8 ± 0.7%, respectively. The
ogy Repo146 K. Berge et al. / Toxicol
measurements were performed at the beginning of the
study and the homogeneity was veriﬁed by measuring EPA
and DHA in 3 samples of the krill powder diet. Both diets
were stored at −20 ◦C to ensure stability of the feed until
given to the animals on a daily discard and top-up routine.
2.4. Observations, body weight and food consumption
Every day during the study the well-being and reac-
tion to treatment of the animals was monitored and once
each week the animals received a detailed clinical exam-
ination. The eyes of the animals were examined before,
during and at the end of the experiment. Body weights were
recorded weekly and the food consumption by each cage of
animals was measured and recorded daily throughout the
treatment period. Water consumption was qualitatively
evaluated by visual inspection every week.
2.5. Haematology, clinical chemistry and urinalysis
At the termination of the study, blood samples for
haematology and clinical chemistry were obtained from all
surviving animals. Samples were obtained from non-fasted
animals via the orbital sinus under isoﬂurane anaesthesia.
0.5 mL  whole blood was transferred into EDTA tubes for
measurement of haematology parameters using the ADVIA
120 automated haematology analyser (Bayer, Munich,
Germany). Haemoglobin, red blood cell count, haemat-
ocrit, white blood cell count, mean cell volume, mean
cell haemoglobin concentration, platelet count, reticulo-
cytes, neutrophils, lymphocytes, monocytes, eosinophils,
basophils and large unclassiﬁed cells were quantiﬁed.
Prothrombin time and activated partial thromboplastin
time were measured in trisodium citrate-treated blood
(blood:citrate ratio of 9:1), with an ACL Advance coagu-
lation analyser (Diamond Diagnostics, MA,  USA). Lithium
heparin tubes were used for blood collected for clinical
chemistry. The tubes were centrifuged and analysed with a
Roche P module clinical chemistry analyser using a Roche
test kit (Roche, Basel, Switzerland) for urea, glucose, aspar-
tate aminotransferase, alanine aminotransferase, alkaline
phosphatase, total protein, albumin, cholesterol, total
bilirubin, calcium and phosphate. Sodium and potassium
was analysed using a Roche P module clinical chem-
istry analyser with an indirect ion selective electrode.
Globulin was calculated by subtraction of the albumin
concentration from the total protein concentration; albu-
min:globulin ratio was calculated by (albumin)/(total
protein − albumin). During week 13, urine samples were
collected over a 4-h period from all animals. They were
deprived of food and water and housed individually in
metabolic cages. The following measurements were per-
formed in fresh urine: volume (weighing of urine sample),
speciﬁc gravity (manual assessment using a refractometer),
colour, pH, protein, glucose, ketones, urobilinogen, biliru-
bin, pigments (Aution JET 9UB test strips using an Aution Jet
AJ4270 analyser, Menarini Diagnostics, Florence, Italy) and
microscopy of the spun deposits (epithelial cells, crystals,
white blood cells, red blood cells, organisms, casts, other
abnormalities).rts 2 (2015) 144–151
2.6. Neurobehavioral studies
During week 12 or 13, detailed neurotoxicological
observations were performed on all animals, including
parameters of a functional observation battery. Most of
the assessments were based on scaled observations of the
animals’ behaviour/status and included home cage and
open ﬁeld evaluations. Moreover, condition of the eyes
and coat, presence of salivation, ease of removal from
cage, body temperature, and overall ease of handling were
recorded. For a period of two  minutes, open ﬁeld obser-
vations in a standardised arena concentrated on: rearing,
grooming, latency, level of mobility, urination/defecation,
tremor/convulsions, vocalisation, arousal, posture, pilo-
erection, palpebral closure, gait abnormalities, stereotypy
and/or unusual behaviours. At a standardised time of the
day, reactions to sound and touching the rump with a
blunt probe were also observed. Landing foot splay, motor
activity, grip strength (using a method derived from Meyer
et al. [19]) and pain perception (using a method derived
from D’Amour [20]) were included as quantitative mea-
surements.
2.7. Pathology
Non-fasted animals were sacriﬁced in a random order
by exsanguination after anaesthesia with carbon dioxide
after 13 weeks of treatment. Body weight of each animal
was  recorded, followed by severance of major blood ves-
sels. All animals were subjected to a detailed necropsy
examination and more than 40 different tissues were
subject to a more comprehensive histopathological exam-
ination. A complete external and internal examination,
which included body oriﬁces, respiratory tract and cranial,
thoracic and abdominal cavities, was performed. Represen-
tative tissues were ﬁxed in 10% neutral buffered formalin or
Davidson’s ﬂuid (only eyes, optic nerve and testis): abnor-
mal  tissue, adrenal glands, aortic arch, blood smear, brain,
eyes, epididymis, gastro-intestinal tract, harderian gland,
heart, implant, kidney and ureter, liver, lung, mesenteric
lymph node, nasal cavity, oesophagus, optic nerve, ovaries,
pancreas, pituitary, prostate, rib, salivary glands, sciatic
nerve, seminal vesicles, spinal cord, skin and mammary
gland, spleen, sternum, submandibular lymph node, testis,
thigh muscle, thyroid with parathyroid, tongue, trachea,
urinary bladder, thymus, uterus and vagina. Sections were
cut 4–6 m thick, and stained with haematoxylin and eosin
(H&E) (unless otherwise stated) and evaluated by a pathol-
ogist. The following organs were weighed: adrenal glands,
brain, epididymides, heart, kidneys, liver, lung, ovaries,
pituitary gland, prostate, spleen, testes, thymus and thy-
roid.
2.8. Statistical analysis
Unless otherwise stated, all statistical tests were two-
sided and performed at the 5% signiﬁcance level using
in-house software and performed as described below.
Pairwise comparisons were performed between the krill
powder and the control group for males and females sepa-
rately. Quantitative data, body weight, food consumption,
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aematology, coagulation, clinical chemistry, urinalysis,
otor activity and quantitative functional observational
attery measurements were analysed for homogeneity of
ariance using the ‘F-Max’ test. If the group variances
ppeared homogeneous, a parametric ANOVA was used
nd pairwise comparisons made using Fisher’s F protected
SD method via Student’s t-test, i.e. pairwise compar-
sons were made only if the overall F-test was signiﬁcant.
f the variances were heterogeneous, log or square root
ransformations were used in an attempt to stabilise the
ariances. If the variances remained heterogeneous, then a
ruskal–Wallis non-parametric ANOVA was used and pair-
ise comparisons made using chi squared protection (via
 tests, the non-parametric equivalent of Student’s t-test).
rgan weights were analysed using ANOVA as above and
y analysis of covariance (ANCOVA) using terminal body
eight as covariate. In addition, organ weights as a percent-
ge of terminal body weight were analysed using ANOVA
s above. Histological incidence data were analysed using
isher’s Exact Probability Test.
. Results
.1. MortalityThere were two animals sacriﬁced prematurely dur-
ng the study. One male animal in the control group was
uthanized on Day 81 of the study having previously
ig. 1. Group mean body weights of male and female Han Wistar rats fed
iets containing krill powder for 13 weeks. No signiﬁcant changes were
bserved between control and krill powder groups (p < 0.05).rts 2 (2015) 144–151 147
displayed clinical observations including abnormal respira-
tion, weight loss, and a subcutaneous mass on left ventral
abdomen. A mammary adenoma was  observed by histo-
logical examination, which could explain the subcutaneous
mass observed at necropsy. Another male animal in the krill
powder group was euthanized on Day 38 due to an open
and wet  lesion on dorsal neck. Histologically, focal ulcerat-
ive dermatitis was  observed, which correlated to the raw
data observed at necropsy.
3.2. Observations, body weight and food consumption
During the 13-week study period, there were no notable
clinical signs that could be related to krill powder treat-
ment. All animals given a krill powder diet, however, were
noted to have abnormal pale and/or yellow coloured fae-
ces. This was considered to be a result of the presence of
astaxanthin in the krill powder (11.2 mg/kg diet) and not to
be of toxicological signiﬁcance [21]. Body weights in both
sexes throughout treatment, were not statistically different
between the control and krill powder groups (Fig. 1). The
food consumption (g/animal/day) in control and krill pow-
der group was  measured weekly for both sexes (Fig. 2), and
were not statistically different between the control and krill
powder groups. Throughout treatment, the overall mean
intake of krill powder was 5357 mg  krill powder/kg body
weight/day for males and 6284 mg  krill powder/kg body
weight/day for females (dosages calculated from data in
Fig. 2. Group mean food consumption of male and female Han Wistar rats
fed diets containing krill powder for 13 weeks. Control and krill powder
groups were not statistically different, except for females consumption at
Week 1 (*p < 0.05).
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Table 2
Haematology and coagulation at termination of the study.
Control Krill powder
Males
Haemoglobin (g/dL) 15.7 ± 0.8 15.5 ± 0.4
Red  blood cells (×1012/L) 8.55 ± 0.70 8.49 ± 0.29
Haematocritt (L/L) 0.43 ± 0.02 0.43 ± 0.01
Mean cell haemoglobin (pg) 18.5 ± 1.5 18.3 ± 0.8
Mean cell volume (fL) 50.6 ± 3.2 50.8 ± 1.5
Mean cell haemoglobin
concentration (g/dL)
36.5 ± 0.9 36.0 ± 1.2
Reticulocytes (%) 1.8 ± 0.3 2.1 ± 0.2
White blood cells (×109/L) 6.41 ± 1.27 6.57 ± 1.31
Neutrophils (×109/L) 1.12 ± 0.37 1.00 ± 0.21
Lymphocytes (×109/L) 5.00 ± 1.04 5.27 ± 1.16
Monocytes (×109/L) 0.10 ± 0.02 0.12 ± 0.03
Eosinophils (×109/L) 0.14 ± 0.05 0.14 ± 0.04
Basophils (×109/L) 0.02 ± 0.01 0.01 ± 0.01
Large unclassiﬁed cells
(×109/L)
0.04 ± 0.01 0.04 ± 0.01
Platelets (×109/L) 747 ± 119 702 ± 182
Prothrombin time (s) 15 ± 1 16 ± 1
Activated partial
thromboplastin time (s)
20 ± 2 22 ± 2
Females
Haemoglobin (g/dL) 15.0 ± 0.6 14.4 ± 0.7
Red  blood cells (×1012/L) 8.06 ± 0.45 7.80 ± 0.41
Haematocritt (L/L) 0.42 ± 0.02 0.40 ± 0.02
Mean cell haemoglobin (pg) 18.6 ± 0.8 18.5 ± 0.4
Mean cell volume (fL) 51.5 ± 1.8 51.2 ± 0.6
Mean cell haemoglobin
concentration (g/dL)
36.1 ± 0.9 36.1 ± 0.8
Reticulocytes (%) 2.6 ± 0.5 2.4 ± 0.8
White blood cells (×109/L) 4.54 ± 0.56 4.81 ± 0.96
Neutrophils (×109/L) 0.62 ± 0.2 0.70 ± 0.37
Lymphocytes (×109/L) 3.71 ± 0.65 3.88 ± 0.90
Monocytes (×109/L) 0.08 ± 0.02 0.10 ± 0.04
Eosinophils (×109/L) 0.09 ± 0.03 0.09 ± 0.04
Basophils (×109/L) 0.01 ± 0.01 0.01 ± 0.01
Large unclassiﬁed cells
(×109/L)
0.03 ± 0.02 0.03 ± 0.01
Platelets (×109/L) 692 ± 108 715 ± 81
Prothrombin time (s) 15 ± 1 14 ± 1
Activated partial
thromboplastin time (s)
21 ± 2 22 ± 3
No signiﬁcant changes were observed between the control and krill pow-
Table 3
Clinical chemistry at termination of the study.
Control Krill powder
Males
Alkaline phosphatase (IU/L) 97 ± 17 104 ± 22
Alanine aminotransferase (IU/L) 23 ± 5 28 ± 4
Aspartate aminotransferase (IU/L) 60 ± 8 60 ± 4
Lactate dehydrogenase (IU/L) 102 ± 27 112 ± 41
Urea (mmol/L) 5.7 ± 0.3 5.8 ± 0.5
Glucose (mmol/L) 11.94 ± 1.57 12.07 ± 1.09
Total bilirubin (mol/L) 1.7 ± 0.0 1.7 ± 0.0
Cholesterol (mmol/L) 1.9 ± 0.2 1.8 ± 0.3
Triglycerides (mmol/L) 2.53 ± 0.60 2.57 ± 0.94
Total protein (g/L) 66 ± 2 69 ± 3a
Albumin (g/L) 42 ± 1 42 ± 1
Globulin (g/L) 24 ± 2 27 ± 2a
Albumin:globulin ratio 1.7 ± 0.1 1.6 ± 0.1a
Sodium (mmol/L) 142 ± 3 143 ± 1
Potassium (mmol/L) 4.2 ± 0.2 4.3 ± 0.2
Phosphate (mmol/L) 1.24 ± 0.27 1.45 ± 0.13
Calcium (mmol/L) 2.68 ± 0.04 2.70 ± 0.09
Females
Alkaline phosphatase (IU/L) 111 ± 76 58 ± 23
Alanine aminotransferase (IU/L) 19 ± 4 21 ± 4
Aspartate aminotransferase (IU/L) 60 ± 8 61 ± 11
Lactate dehydrogenase (IU/L) 73 ± 10 158 ± 202
Urea (mmol/L) 7 ± 0.9 5.8 ± 0.6
Glucose (mmol/L) 10.75 ± 1.48 9.26 ± 1.20
Total bilirubin (mol/L) 1.9 ± 0.5 1.7 ± 0.0
Cholesterol (mmol/L) 1.2 ± 0.3 1.2 ± 0.3
Triglycerides (mmol/L) 1.39 ± 0.78 1.70 ± 0.76
Total protein (g/L) 69 ± 3 73 ± 4a
Albumin (g/L) 49 ± 3 51 ± 4
Globulin (g/L) 19 ± 2 22 ± 2b
Albumin:globulin ratio 2.6 ± 0.3 2.4 ± 0.3
Sodium (mmol/L) 141 ± 1 142 ± 1
Potassium (mmol/L) 3.6 ± 0.2 3.9 ± 0.3a
Phosphate (mmol/L) 1.12 ± 0.24 1.26 ± 0.23
Calcium (mmol/L) 2.68 ± 0.04 2.70 ± 0.08
All values are means ± SD for 8–10 animals.
considered to be related to the consumption of the krill
powder diet in either of the sexes were seen (Table 4).
Table 4
Urinalysis at termination of the study.
Control Krill powder
Males
Urine speciﬁc gravity 1.055 ± 0.012 1.064 ± 0.011
Urine volume (mL) 0.7 ± 0.5 0.4 ± 0.3
pH  8.0 ± 1.1 7.3 ± 1.1
Females
Urine speciﬁc gravity 1.058 ± (–) 1.052 ± 0.000
Urine volume (mL) 0.1 ± 0.0 0.2 ± 0.2
pH  6.6 ± 0.5 7.3 ± 1.2
No signiﬁcant changes were observed between the control and krill pow-
der  groups (p < 0.05). All values are means ± SD. The number of samples
in  males was: urine speciﬁc gravity: n = 7–9; urine volume: n = 9; pH:der  group (p < 0.05). All values are means ± SD for 6–10 animals.
Tables 2 and 3). Visual inspection of water bottles did not
show any differences between the groups throughout the
treatment period.
3.3. Haematology, clinical chemistry and urinalysis
Haematology values at the termination of the study
are presented in Table 2. There were no differences in
any of the parameters that were considered to be due to
the consumption of krill powder. There were, however,
some signiﬁcant changes in clinical chemistry measure-
ments (Table 3). Total protein was increased signiﬁcantly in
both males and females fed the krill powder diets. Globulin
levels in the krill powder fed animals were also signiﬁcantly
increased in both sexes, compared to control. This led to a
decrease in the albumin:globulin ratio, but in male animals
only. The fourth statistically different observation was ana p < 0.05 (signiﬁcantly different from control).
b p < 0.01 (signiﬁcantly different from control).
increase in potassium level in female rats fed the krill pow-
der diet. No differences in urinalysis parameters that weren  = 8–9. The number of samples in females was: urine speciﬁc gravity:
n  = 1–2; urine volume: n = 6–10; pH: n = 4–5. (–): Due to the small number
of  female samples, an accurate comparison could not be made against the
control group, although no numerical differences were noted.
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Table  5
Relative organ weights (% of body weight).
Control Krill powder
Males
Adrenals 0.013 ± 0.002 0.012 ± 0.001
Brain 0.43 ± 0.04 0.42 ± 0.04
Epididymides 0.29 ± 0.05 0.28 ± 0.04
Heart 0.29 ± 0.02 0.27 ± 0.02
Kidneys 0.61 ± 0.02 0.60 ± 0.06
Liver 3.3 ± 0.2 3.6 ± 0.4
Lung 0.38 ± 0.04 0.40 ± 0.05
Pituitary 0.0018 ± 0.0003 0.0024 ± 0.0008
Prostate 0.10 ± 0.02 0.11 ± 0.02
Spleen 0.15 ± 0.02 0.15 ± 0.01
Testes 0.76 ± 0.09 0.76 ± 0.10
Thymus 0.11 ± 0.02 0.12 ± 0.04
Thyroid 0.0057 ± 0.0012 0.0057 ± 0.0018
Females
Adrenals 0.029 ± 0.007 0.029 ± 0.007
Brain 0.70 ± 0.09 0.73 ± 0.06
Heart 0.34 ± 0.04 0.33 ± 0.03
Kidneys 0.66 ± 0.08 0.69 ± 0.05
Liver 3.2 ± 0.3 3.6 ± 0.4
Lung 0.54 ± 0.09 0.54 ± 0.07
Ovaries 0.042 ± 0.008 0.043 ± 0.007
Pituitary 0.0045 ± 0.0007 0.0049 ± 0.0009
Spleen 0.21 ± 0.02 0.23 ± 0.02
Thymus 0.17 ± 0.04 0.15 ± 0.01
Thyroid 0.0075 ± 0.0016 0.0076 ± 0.0014
Uterus 0.25 ± 0.16 0.24 ± 0.06
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Table 6
Absolute organ weights (g).
Control Krill powder
Males
Final body weight 481 ± 51 477 ± 23
Adrenals 0.062 ± 0.007 0.056 ± 0.008
Brain 2.05 ± 0.05 1.96 ± 0.05
Epididymides 1.36 ± 0.17 1.35 ± 0.19
Heart 1.36 ± 0.13 1.26 ± 0.09a
Kidneys 2.95 ± 0.34 2.86 ± 0.33
Liver 15.96 ± 1.95 17.30 ± 2.52
Lung 1.82 ± 0.17 1.87 ± 0.27
Pituitary 0.009 ± 0.001 0.012 ± 0.004
Prostate 0.49 ± 0.1 0.54 ± 0.09
Spleen 0.69 ± 0.05 0.70 ± 0.07
Testes 3.62 ± 0.27 3.59 ± 0.46
Thymus 0.54 ± 0.09 0.51 ± 0.13
Thyroid 0.027 ± 0.005 0.027 ± 0.009
Females
Final body weight 263 ± 38 247 ± 16
Adrenals 0.076 ± 0.016 0.073 ± 0.016
Brain 1.82 ± 0.08 1.79 ± 0.14
Heart 0.90 ± 0.12 0.82 ± 0.07a
Kidneys 1.71 ± 0.2 1.69 ± 0.12
Liver 8.43 ± 1.01 8.77 ± 1.06
Lung 1.40 ± 0.24 1.32 ± 0.17
Ovaries 0.11 ± 0.02 0.11 ± 0.02
Pituitary 0.012 ± 0.002 0.012 ± 0.002
Spleen 0.55 ± 0.08 0.56 ± 0.05
Thymus 0.44 ± 0.12 0.36 ± 0.05
Thyroid 0.020 ± 0.005 0.019 ± 0.003
Uterus 0.65 ± 0.44 0.58 ± 0.17
All values are means ± SD for 8–10 animals.
a p < 0.05 (signiﬁcantly different from control).
Table 7
Necropsy and histological ﬁndings.
Control Krill powder
Males (n = 10)
Liver lobulation 0 4
Hepatocyte vacuolation 0 2
Females (n = 10)
Liver lobulation 0 0
Hepatocyte vacuolation 0 0o signiﬁcant changes were observed between the control and krill pow-
er  groups (p < 0.05). All values are means ± SD for 8–10 animals.
.4. Neurotoxicity, neurobehavioral studies and
phthalmoscopy
There were no abnormalities detected in the brain in
ny animal after histological evaluation at the termination
f the study. Moreover, there were no test material-related
hanges in motor activity for either sex. Likewise, krill pow-
er administration did not affect any of the parameters
easured by a functional observation battery of assess-
ents that included landing foot splay, fore grip, hind grip
nd tail ﬂick. There were no ophthalmoscopy ﬁndings that
ere considered to be related to administration of krill
owder for 13 weeks.
.5. Pathology
Both relative (Table 5) and absolute (Table 6) organ
eights are presented. We  observed a decreased absolute
eart weight in both sexes, compared to control animals.
owever, after adjustment for body weight, no signiﬁcant
hanges in heart weights were observed.
After krill powder administration for 13 weeks, promi-
ent liver lobulation was observed in 4 out of 10 males,
ut not in any of the female animals (Table 7). Peripor-
al microvesicular hepatocyte vacuolation was observed in
 out of 10 males which received the krill powder diet,
ut this ﬁnding was not statistically different, when com-
ared with the control animals (p < 0.05). This correlated
ith the ﬁndings of prominent liver lobulation in 4 male
nimals observed at necropsy. Since the hepatocyte vac-
olation in the two male animals was not associated withNecropsy (prominent liver lobulation) and histopathology (periportal
microvesicular hepatocyte vacuolation) was done in 10 male and female
animals after 13 weeks of control or krill powder treatment.
hepatocellular necrosis or inﬂammation, and clinical
pathology ﬁndings suggesting liver impairment was not
detected, this ﬁnding was  considered adaptive and non-
adverse. There were no liver vacuolation observations in
females receiving krill powder or in control animals.
4. Discussion
This 13-week subchronic toxicity study in rats using krill
powder at a dose of 9.67% in the diet demonstrates a lack
of toxicologically signiﬁcant adverse effects and demon-
strates that krill powder is a safe source of omega-3 fatty
acids. The 9.67% dose of krill powder was chosen since it
corresponds to a dose of 5% krill oil, which was previously
found to be the NOAEL in a 13-week toxicity study [22].
Given that the effects of the toxicity study were not adverse
in nature, the NOAEL for the conditions of this study was
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considered to be 9.67% krill powder (equating to 5357 mg
krill powder/kg body weight/day for males and 6284 mg
krill powder/kg body weight/day for females). However,
since only one dose of krill powder was used in this study,
no deﬁnitive statement on NOAEL can be made, which
should be seen as a limitation to this study.
No differences were noted in body weight or food
consumption during the krill powder treatment. Adminis-
tration of krill powder resulted in abnormally pale and/or
yellow coloured faeces, which was considered a result of
the test diet which itself had a red colour due to the astax-
anthin content in krill powder. One animal in the krill
powder group was euthanized during the study due to
an open and wet lesion on dorsal neck. Even if no signiﬁ-
cant alterations was observed in haematology parameters,
some differences in clinical chemistry values (total pro-
tein, globulin and potassium levels) were noted in the krill
powder-treated group, when compared to control. How-
ever, the ﬁndings were considered to be of no toxicological
signiﬁcance since the changes were small and not related
to histopathological changes.
Hepatocyte vacuolation was observed in two male rats
fed krill powder after microscopic evaluation. This might
be due to an accumulation of triglycerides in the liver due
to the high dose of lipids given [23]. Such observations
has been seen in other studies and is considered to be a
compensatory transient process [24].
Signiﬁcantly decreased absolute heart weights for both
male and female animals receiving krill powder was
observed in the study. In a previous study with Zucker
rats, a decreased amount of fat in the heart after krill oil
treatment was  observed [11]. The decreased heart weight
observed in the current study could possibly be explained
by similar fat-lowering mechanisms. However, when eval-
uated relative to body weight, the heart weight was  not
signiﬁcantly altered in the krill powder animals, when
compared to the control group.
In conclusion, krill powder demonstrated no adverse
toxicological in-life, haematology or clinical chemistry
effects at an inclusion level of 9.67% in diets for rats, when
given for 13 weeks. The negative ﬁndings were restricted
to hepatocyte vacuolation in male animals with no accom-
panying increase in liver weight.
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